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                                                                  AIM 
 
“To study the role of diffusion weighted MRI imaging in predicting the response to concurrent 
chemoradiotherapy in patients with nasopharyngeal carcinoma 
 
                                                OBJECTIVE 
 
Primary Outcome: To study the role of diffusion weighted MRI derived parameters i.e. ADC 
as an imaging biomarker in nonmetastatic nasopharyngeal carcinoma. 
 
Secondary Outcome: Validating the role of diffusion weighted in detection and 
characterization of nasopharyngeal cancers as well as for monitoring the response to 
radiotherapy and chemotherapy. 
 
                                           HYPOTHESIS 
 
Diffusion weighted imaging plays a key role in prediction of treatment response to chemo-
radiotherapy in patients diagnosed with nasopharyngeal malignancies 
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INTRODUCTION 
 
According to the Globocan fact sheet, worldwide there are approximately 60,896 new 
nasopharyngeal cases and a reported of 35,756 deaths annually. In India, there are about 3947 
cases being reported annually with nasopharyngeal malignancy. 
Carcinomas of Nasopharynx are known to be radio-responsive and are treated using radiation 
therapy with or without chemotherapy. The standard of care for the treatment of patients with 
non-metastatic nasopharyngeal cancer is radiotherapy with or without chemotherapy. Based 
on the stage, they receive radiation alone or concurrent chemoradiotherapy followed by 
adjuvant chemotherapy. Some patients receive chemotherapy prior to Radiation to decrease 
the size of the tumor or lymph nodes especially if they lie close to critical structures in the head 
& neck region e.g. optic apparatus brainstem & the spinal cord. However, nearly in 7%–13% 
of cases residual disease persists after treatment. Moreover, the appearance of local or distant 
relapse determines a less favorable prognosis for these patients. Salvage treatment options are 
with limited success. Thus, it is essential to be able to predict and monitor the therapeutic 
response of patients with Carcinoma Nasopharynx. Hence attempts are being made to predict 
response to radiation therapy with various functional and metabolic imaging.  
Anatomic imaging (CT and MR imaging) is focused on diagnosing and/or characterizing the 
disease, defining its local extent, and evaluating distant spread. While the accurate assessment 
of the biologic status of the cancer (cellularity, growth rate, response to chemoradiation 
therapy) with functional imaging modalities like dynamic contrast enhancement MRI, 
diffusion weighted MRI, FDG PET can be essential for prognostication, planning therapy, and 
follow-up of lesions after therapy. The combination of anatomic and biologic imaging 
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techniques can thus provide a more comprehensive evaluation of the patient helping in better 
understanding of the pathophysiology of the disease and allowing better evaluation of 
treatment strategies.  
This study is mainly focused on evaluating the role of Diffusion-weighted Magnetic Resonance 
Imaging (DW MRI) in predicting early response to chemoradiation in nasopharyngeal 
malignancies. DW MRI explores the random motion of water molecules in the tissue. Water 
molecules are in a constant random movement called the Brownian motion. The Diffusion 
Weighted signal in biologic tissues is derived from the motion of water molecules in the 
intracellular space, the extracellular space, and the intravascular space. The degree of 
restriction to water diffusion in biologic tissue is inversely correlated to the tissue cellularity 
and the integrity of cell membranes. The motion of water molecules is more restricted in tissues 
with a high cellular density associated with numerous intact cell membranes (e.g., tumor 
tissue). The lipophilic cell membranes act as barriers to motion of water molecules in both the 
extracellular and intracellular spaces. By contrast, in areas of low cellularity or where the 
cellular membrane has been breached, the motion of water molecules is less restricted. A less 
cellular environment provides a larger extracellular space for diffusion of water molecules, and 
these molecules may also freely.  
Effective anticancer treatment results in tumor lysis, loss of cell membrane integrity, increased 
extracellular space, and, therefore, an increase in water diffusion. Impediments such as cell 
membranes, organelles, and macromolecules interferes with the free movement of water 
molecule, this diffusion in biological tissue is quantified by means of an APPARENT 
DIFFUSION COEFFICIENT (ADC). 
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Malignant tissues have more densely packed cells as compared to their nonmalignant 
counterparts. Thus, the “diffusion” of water molecules is restricted due to high cellularity in 
malignant tissue.  With radiation therapy, there is cell death and increased water movement 
across tumor and thus increased diffusion which in turn is expressed in increase in ADC values. 
Therefore, as treatment progresses, the ADC values are expected to rise as the tumour cells 
respond to the chemoradiation. Thus, the serial monitoring of the ADC values before radiation, 
during radiation and at 6 weeks after radiation will help in correlating the ADC values of the 
responders and non-responders. We chose the time periods for assessment as  
1. Pre-RT:  Prior to initiation of radiation therapy 
2. Week 1: At 1 week of radiation therapy 
3. Follow up: At 4-6 weeks after completion of RT 
This response evaluation can be utilized for tailoring treatment for patients in the future. 
Therefore, patients showing response utilizing Diffusion weighted imaging may not need 
further chemotherapy. The purpose of this study was to evaluate the usefulness of DW MRI 
with ADC values in predicting the responses to radical chemoradiotherapy in nasopharyngeal 
malignancies  
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REVIEW OF LITERATURE 
 
Epidemiology 
 
Nasopharyngeal carcinoma(NPC) is a rare malignancy worldwide but is seen in high incidence 
in Sothern China, Hongkong and South-east Asia. These areas are termed “High-risk” or 
“Endemic” for NPC. According to the Globocan fact sheet, worldwide there are approximately 
60,896 new nasopharyngeal cases and a reported of 35,756 deaths annually. 
According to the Indian data there are about 3947 cases being reported annually with 
nasopharyngeal malignancy(1) 
 
 
 
 
 
 
 
 
 
 
 
Table 1: The WORLD Incidence, mortality and 5year prevalence – adopted from the Globocan 
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Table 2: The INDIAN Incidence, mortality and 5year prevalence of nasopharyngeal cancers – 
adopted from the Globocan  
 
 
Though NPC is a rare malignancy in the Indian subcontinent, the North-eastern tribes are 
reported to be an intermediate risk population with an average incidence of 4.3 per 100,000 
people/year(2).  NPC is often misdiagnosed and underreported. Hence the actual incidence can 
be higher than reported. Highest incidence in our country is reported from the Imphal district 
of Manipur, closely followed Manipur and Sikkim. 
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ESTIMATED BURDEN – 2020 
 
Fig 3: Estimated incidence of Nasopharyngeal malignancies by 2020 in India 
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Fig 6: Estimated deaths due to Nasopharyngeal malignancy by 2020 in India 
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Anatomy of nasopharynx 
The nasopharynx is a tubular space situated below the base of the skull. It is a part of the 
Waldeyer ring. It is lined by stratified squamous epithelium and ciliated epithelium. NPC is 
commonly developing from the lateral wall of nasopharynx, particularly at the fossa of 
Rosenmuller.  
 
Figure 7: Sagittal section of human head showing Nasopharynx (Highlighted in yellow) 
BOUNDARIES OF NASOPHARYNX 
Anterior Posterior nares and posterior nasal septum 
Posterior C1 and C2 vertebral bodies 
Retropharyngeal space 
 
Superior Basi-sphenoid and Basi-occiput 
Inferior Anteriorly: Soft palate 
Posteriorly: Communicates with Oropharynx via Nasopharyngeal 
isthmus  
Lateral Contains opening of Eustachian tube 
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NEUROVASCULATURE 
Arterial supply Ascending pharyngeal Artery 
Facial Artery 
Ascending cervical artery  
Venous drainage Pterygoid and Pharyngeal Plexus 
Lymphatic drainage Lateral lymphatic channels  Lateral retropharyngeal, deep 
cervical and posterior triangle nodes 
Medial lymphatic channels  Median retropharyngeal nodes 
Nerve innervation Sensory – V & IX cranial nerve branches 
Motor – Pharyngeal plexus 
 
Synonyms for NPC: The first description of NPC as “Skull base tumor” dates to 1845. In 1921, 
it was termed “lymphoepithelioma” by Regaud and Schmincke. 
Risk Factors 
 
The risk factors most frequently associated with nasopharyngeal carcinoma are ethnicity, 
smoking and Epstein Barr Virus (EBV) infection. 
 
Ethnicity – Nasopharyngeal carcinoma (NPC) is a very common neoplasm in Southern 
Chinese and south-east Asians. China along with southeast Asia is considered an endemic 
region for NPC.  Southern Chinese who have migrated to non-endemic regions are found to 
have a decline in incidence of NPC compared to their counterparts residing at homeland. Yet, 
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they continue to have higher incidence rate compared to other ethnic groups residing in the 
same geographical regions.(3) Ethnicity shadows genetic susceptibility. 
Genetic Predisposition – There has been much debate over genetic predisposition in 
nasopharyngeal malignancies. A review of Genome-wide association studies (GWAS) showed 
association of immune related genes with NPC.  DNA repair genes, Classical and Non-classical 
HLA genes are found to have a strong association with NPC in the Chinese (4). The association 
in the non-endemic region needs to be proven yet. 
Familial aggregation of NPC has also been reported.  
 
Epstein Barr virus infection – EBV infection is a well-known causal factor in NPC. Epstein- 
Barr virus (EBV) infection has been linked with the non-keratinising subtypes of 
nasopharyngeal cancers. High pre-treatment plasma EBV DNA titres correlate with higher 
stage of disease and persistent EBV DNA titres after treatment are associated with poor 
prognosis. EBV DNA is now an established biomarker for prognosticating outcomes after 
treatment.  
 
Smoking – Smoking tobacco products (cigarettes, cigars, pipes) is an important risk factor for 
the development of NPC. It is a major factor in development of NPC in non-endemic areas. 
Association of smoking was found with well differentiated histology rather than an 
undifferentiated histology. Furthermore, those with > 30 pack-years had double the incidence 
of NPC than those with < 30 pack-years. From a recent Metanalysis, the pooled risk estimate 
for nasopharyngeal malignancy associated with each 1-pack-year increment of smoking was 
1.019 (5). 
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Alcohol — Like smoking, alcohol intake was also found to have increased the risk of well 
differentiated NPC. The quantitative relationship is however complex. Results from a 
Systematic review showed a J shaped pooled dose response curve indicating that risk of NPC 
decreases up to 15 drinks/week and thereafter increases with further increase in alcohol intake. 
Confounding factors like smoking and salted fish could have led to such a conclusion.(6) 
 
Occupational exposure — Multiple other occupational or environmental toxins have been 
studied for potential relationship with NPC. Formaldehyde, wood dust and fumes are known 
carcinogens(7). 
 
Radiation — Prior irradiation for either malignant or benign disease has been linked to thyroid 
cancer, salivary gland tumors, squamous cell cancers, and sarcomas.  Although this 
relationship appears to be real, its relevance in NPC is unclear.  
 
Diet — Some dietary factors may have a role in protecting individuals from head and neck 
cancer, while others may increase susceptibility for specific diseases. Salted fish and 
preservatives in food items are for long thought to be one of the causal factors of NPC 
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Clinical presentation 
 
Nasopharyngeal malignancies can spread through local, lymphatic and hematogenous 
pathways. Symptoms and its severity varies according to the site and extent of involvement. 
Owing to its proximity to base of skull and sinuses, it can often present with cranial nerve 
involvement. Common symptoms secondary to local spread are described below as a flow 
diagram
 
 
Lymphatic spread assumes great significance in NPC as nasopharynx has a rich lymphatic 
network. The retropharyngeal group of lymph nodes are believed to be the first echelon nodes 
and the risk of involvement of deep cervical nodes unilaterally or bilaterally is the highest in 
NPC in comparison to any other head and neck tumor. As high as 70% of patients present with 
nodal involvement at presentation and lymph node enlargement is the most common clinical 
presentation. It also is an important prognostic factor in NPC. 
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Distant metastases are not very uncommon in NPC. The common sites of involvement are 
bone, liver and lung. Nodal involvement and the site of lymphadenopathy predicts distant 
metastatic potential. 
Diagnostic Evaluation 
 
NASOPHARYNGOLARYNGOSCOPE (NPL): The flexible fibreoptic 
Nasopharyngolaryngoscopy is a very valuable tool that can visualise Nasopharynx and 
structures around it 
It helps in  
- Identifying the site and extent of the disease 
- Biopsy and  
- Stage the disease. 
BIOPSY: The histopathology is the gold standard for diagnosis of NPC. ls called squamous 
cells. The WHO classification of NPC began in 1978 and has had multiple revisions since then. 
The most recent classification in 2005 divides NPC into three histological subtypes: 
1. Keratinizing squamous cell carcinoma 
- Well differentiated / Moderately differentiated / Poorly differentiated 
2. Non-Keratinizing carcinoma 
- Undifferentiated / Differentiated 
3. Basaloid carcinoma 
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Non-keratinizing carcinoma is the most common (~90%) variant in endemic areas (high risk 
areas). Keratinizing is relatively rare and is seen in high incidence in patients with smoking 
and alcohol abuse. Basaloid is the rarest variety (~1%). Association with EBV was found in 
Non-keratinizing and Basaloid types. 
IMAGING: The anatomy of nasopharynx presents structural and functional variations, 
making precise diagnosis and staging a challenging task. NPL scopy will not be able to exactly 
stage disease, Example: Intracranial extension which is identified on cross-sectional imaging 
may be missed in a routine NPL scopy. There is a greater need for precise staging of the disease 
as survival varies with each stage and so is the treatment planning.  
Cross-sectional imaging was revolution since its invention in the mid seventies. Anatomical 
imaging techniques such as Computerized Tomography (CT) and Magnetic resonance imaging 
(MRI) provide morphological information while the evaluation of biological characteristics of 
tumors is by the functional imaging modalities.  
1. Computed Tomography:  CT can identify tumor in the nasopharynx based upon 
anatomic distortion and/or specific tumor enhancement. In general, tumors enhance 
more than normal structures except for mucosa, extraocular muscles, and blood vessels. 
Compared with MRI, CT provides greater spatial resolution, and can be performed 
faster, thereby eliminating motion artefact, and it is better for the evaluation of bone 
destruction such as skull base erosion seen in T3 disease. Modern multidetector CT 
technology allows scanning to be performed with slice thickness less than 1 mm. Slice 
thickness of 3 mm is generally optimal. 
• Primary site — For primary site, contrast-enhanced CT can help determine the extent 
of tumor infiltration into soft tissue and bone. CT can provide information on invasion 
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of the para-pharyngeal space, sinuses and skull base invasion. The modern technology 
of dual energy and multispectral CT has demonstrated improved accuracy for assessing 
bone invasion compared with conventional CT. Asymmetry is a feature suggestive of 
malignant process in nasopharynx in the initial stages. However, clinical relevance of 
such asymmetry is difficult to interpret on CT because of inflammatory process, 
lymphoid tissue and secretions in nasopharynx. Presence of minor asymmetry is often 
mistaken for disease and results in false positivity. A modified Valsalva manoeuvre 
which opens collapsed lateral pharyngeal recess can be tried during CT. Also, 
occasionally CT may fail to depict an early cortical erosion of the skull base that is 
better depicted on MRI. 
• Regional nodes — Imaging by CT or MRI is complementary to the clinical 
examination for the staging of the neck lymph nodes. CT evaluation of regional lymph 
nodes primarily relies upon size criteria as well as the appearance of lymph nodes to 
differentiate involved from uninvolved lymph nodes. The use of size criteria alone 
results in frequent false positive and false negative assessment of regional nodes. CT is 
also highly sensitive for detection of extracapsular spread of tumor.  
Pathologic lymphadenopathy is usually identified radiologically as a node greater than 
10 to 11 mm in minimal axial diameter or presence of central necrosis. In general, 
criteria based on measurement of minimal axial diameter are considered the most 
accurate, effective and probably most reproducible. Other features pointing towards 
lymph nodal involvement by malignancy include rounded shape, loss of normal fatty 
hilum, and increased or heterogeneous contrast enhancement. Although CT is superior 
to clinical examination, the implementation of size criteria and presence of central 
necrosis limit detection of borderline-sized nodes, non-necrotic nodes. CT cannot 
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differentiate between reactive and normal nodes. This is a critical issue since 
microscopic or occult lymphadenopathy is very common in NPC which is known for 
its high lymphatic spread. 
1. Magnetic Resonance Imaging(MRI) : MRI provides superior soft tissue definition 
compared with CT  and can often provide information that is complementary to CT. 
Moreover, there is no use of non-ionizing radiation with MRI.  Most important imaging 
sequences for include non-contrast enhanced T2-weighted images and contrast T2 and 
T1 sequences. Images in axial and coronal plane are the most useful. For general 
purpose, slice thickness should be no more than 5 mm. Some applications, such as 
evaluation of skull base and perineural spread, may require thinner slice thickness, 
typically around 3 mm. 
• Primary site – As the soft tissue is better seen on MRI than CT, it adds to the 
information generated from CT. MRI is also better than CT for discriminating tumor 
from mucus and in detecting bone marrow invasion. MRI is superior to CT for 
evaluation of perineural spread, para-pharyngeal extension, skull base invasion, and 
intracranial extension. MRI may also provide additional benefits compared with CT in 
the evaluation of the base of tongue involvement and parotid glands. 
• Regional nodes - Fat surrounding the nodes decreases their prominence on the MRIs. 
Fat-suppressed contrast-enhanced sequences are the optimal sequences for detecting 
nodal metastasis. The retropharyngeal nodes, which are the echelon nodes, are easily 
detected on MRI. 
 
2. 18 Flurodeoxyglucose PET (FDG PET):  With PET, injected positron-emitting 
radionuclides, such as fluorine-18, are taken up by metabolically or functionally active 
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tissues. PET images are created by detecting these emissions by an array of detectors 
and then using reconstruction techniques to create a three-dimensional image. The most 
commonly used agent is 18F-flourodeoxyglucose (FDG), which is taken up into cells 
in different concentrations depending on the relative metabolism of different tissues. It 
is specific for tumors because metabolic rates are very high in many tumors.  
Imaging of the primary tumor site and regional lymph nodes with PET is limited by its 
poor spatial resolution, which can make it difficult to localize the anatomic location of 
the FDG uptake. These issues can be at least partially addressed with integrated PET-
CT imaging, in which PET and CT are performed sequentially during a single visit on 
a hybrid PET-CT scanner. The images are then co-registered using fusion software, 
enabling the physiologic data obtained on PET to be localized according to the anatomic 
CT images. 
• Primary site - Historically, CT images obtained from integrated PET-CT scanners had 
lower spatial resolution compared with dedicated CT scanners. This problem is now 
being overcome by new generation of PET-CT scanners that offer volumetric CT 
capability. Thus, currently PET appears to be at least as sensitive and specific as CT 
and MRI in detecting primary head and neck tumors.   
• Regional nodes - More importantly, PET is superior to both CT and MRI for detecting 
regional nodal metastases, as well as second primary tumors(10) Data indicates 
that PET/CT is accurate for detecting occult cervical nodal metastases, although it does 
not have the sensitivity to replace neck dissection. However false negatives of PET may 
be seen in lymph nodes less than 5 mm, necrotic or cystic lymph nodes, and tumors of 
low metabolic activity. 
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• Distant metastases -Its main utility is in finding distant metastases, unknown primary 
lesions, and synchronous second primary tumors. 
 
An updated Metanalysis comparing CT Vs MRI Vs PET-CT showed the following results(11) 
 CT MRI PET CT 
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
Local site – T staging 0.84 0.80 0.95 0.76 0.85 0.91 
Nodal site – N 
staging 
0.92 0.93 0.88 0.95 0.88 0.95 
Authors have concluded by stating that MRI was more accurate than CT or PET-CT in local 
staging and fairly comparable in nodal staging. PET-CT is preferred for detecting occult neck 
nodes, metastatic disease, synchronous second primaries and recurrences. 
Staging of the Disease 
 
Currently we are following the 7th edition of AJCC/UICC staging system. However, the 8th 
edition which would come into effect from January 2018 has major modifications in NPC 
staging. We had followed the 7th edition in our study. 
The 7th and 8th editions are both presented below: 
7th EDITION AJCC STAGING T 
stage 
8th EDITION AJCC STAGING 
Tumor confined to Nasopharynx or 
extension to oropharynx / nasal cavity 
T1 Unchanged 
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Extension to: 
- Para-pharyngeal space 
 
T2 Extension to: 
- Para-pharyngeal space 
- Pterygoid muscle (Medial / 
lateral) 
- Prevertebral structure 
Invading: 
- Skull base 
- Paranasal sinuses 
T3 Invading: 
- Skull base 
- Paranasal sinuses 
- Pterygoid structures 
- Cervical vertebrae 
Any invasion into 
- Infratemporal fossa  
- Masticator space 
- Hypopharynx  
- Orbit 
- Intracranial extension 
- Cranial nerve involvement 
 
T4 Any invasion into: 
- Parotid gland 
- Beyond lateral surface of lateral 
pterygoid 
- Hypopharynx  
- Orbit 
- Intracranial extension 
- Cranial nerve involvement 
Changes are highlighted in Bold Italics 
 
 Changes are highlighted in Bold Italics  
7th EDITION AJCC STAGING Nodal 8th EDITION AJCC STAGING 
< 6 cms in greatest dimension,  
above supraclavicular fossa 
- Unilateral metastases, in cervical 
lymph nodes (or) 
- Unilateral / Bilateral metastases in 
retropharyngeal nodes 
N1 < 6 cms in greatest dimension,  
above the caudal border of cricoid cartilage  
- Unilateral metastases, in cervical 
lymph nodes (or) 
- Unilateral / Bilateral metastases in 
retropharyngeal nodes 
< 6 cms in greatest dimension,  
above supraclavicular fossa 
- Bilateral cervical nodes 
N2 < 6 cms in greatest dimension,  
above the caudal border of cricoid cartilage  
- Bilateral cervical nodes 
>6 cms in greatest dimension (and / or) 
 
N3 >6 cms in greatest dimension (and / or) 
 
In the supraclavicular Below the caudal border of cricoid 
cartilage  
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7th EDITION AJCC STAGING STAGE 
GROUP 
8th EDITION AJCC STAGING 
T1 N0 M0 I T1 N0 M0 
T1 N1 M0  
II 
T1 N1 M0 
T2 N0/1 M0 T2 N0/1 M0 
T1/2 N2 M0  
III 
T1/2 N2 M0 
T3 N1/2 M0 T3 N1/2 M0 
T4 N0/1/2 M0  
IV A 
T4 N0/1/2 M0 
Any T N3 M0 
Any T N3 M0 IV B Any T Any N M1 
Any T Any N M1 IV C  No longer exists 
 
Treatment of Non-Metastatic Nasopharyngeal malignancies 
 
EARLY DISEASE (T1 N0 M0): Radiotherapy alone is treatment for early disease. According 
to Song et al. use of chemotherapy has not shown additional benefit in stage I NPC(12). In 
another study, the 10-year disease specific survival, recurrence free survival and distant 
metastasis free survival rates were all over 95% with radiation alone(13). Guidelines by the 
European Society for Clinical Oncology -ESMO (14), the Spanish Society of Medical 
Oncology -SEOM(15) and National Comprehensive Cancer Network - NCCN(16) suggest RT 
alone is an optimal modality of therapy for T1N0M0 NPC. 
LOCALLY ADVANCED DISEASE (T1, N1–3; T2–4, Any N, M0): Addition of 
chemotherapy both concurrently and as adjuvant was found to survival advantage in locally 
advanced NPC in multiple studies. Landmark Intergroup study by South-west Oncology Group 
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(SWOG) showed increased survival with concurrent chemoradiotherapy (CRT) followed by 
adjuvant chemotherapy compared to radiotherapy alone in  stage III and IV carcinoma 
nasopharynx patients(17).  The benefit combined therapy in Stage III and IV is undebated. 
Stage II NPC has remained an enigma for most clinicians with conflicting evidence on addition 
of chemotherapy to radiation. Most studies on CRT excluded stage II NPC.  Cheng et al. (18)  
showed that disease-free survival in stage II NPC with CRT is equal to that of patients with 
stage I disease with radiation alone.  While SEOM(15) recommends radiation alone for stage 
II, both ESMO(14) and NCCN(16) recommend CRT.  
Metanalysis of 2138 stage II NPC patients by Cheng Xu et al. had shown chemoradiation to 
have significantly higher overall survival and locoregional relapse free survival compared to 
RT alone(19). But there was no difference in distant metastases free survival. Moreover, the 
equivalence of RT alone with chemoradiation was seen when IMRT was used in subgroup 
analysis. Also grade 2/3 toxicities were lesser in IMRT group compared to chemoradiation 
group. This lead the authors to the conclude that chemoradiation was superior to 2D 
radiotherapy but the same does not hold true for IMRT in stage II NPC. 
ROLE OF INDUCTION / NEOADJUVANT CHEMOTHERAPY:   A pooled data 
analysis was conducted by Chua et al. of two phase III studies (n=784). It showed that the 
addition of platinum-based induction chemotherapy to radiation had caused decrease in relapse 
by 14.3%. The cancer-related deaths reduced by 12.9 percent at 5 years. However, there was 
no improvement in overall survival (61.9 % Vs. 58.1 %, p=0.092). This could be attributed to 
more late intercurrent deaths in both the groups(20)  
Other benefit of Induction chemotherapy is downsizing tumor which could be very useful in a 
complex structure like nasopharynx where the tumor can lie close to many critical structures 
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making the dose delivery to tumor a challenge without limiting the organs at risk (OAR) dose. 
In our institution, we follow induction/neoadjuvant chemotherapy whenever there is high 
tumor bulk or when the lesion is close to critical OARs.  
 
Role of Intensity Modulated Radiation Therapy (IMRT) 
 
Tumor control for carcinoma nasopharynx highly correlates with the tumor dose. In a 
retrospective review of 85 patients with NPC, an improved local control was seen when the 
tumor received > 67 Gy(21). In another series having 118 patients, the improved tumor control 
was not just due to higher doses delivered to tumor, but also due to improvements in technical 
accuracy(22). As nasopharynx is surrounded by many critical structures, accuracy in dose 
delivery is very important in dose escalation. 
Intensity-modulated radiation therapy allows very high dose to be delivered to the tumor while 
sparing the surrounding critical structures. These critical structures include the salivary glands, 
optic apparatus, brainstem, spinal cord and the auditory apparatus. In addition, IMRT can 
deliver a higher dose per fraction which yields a biologically more effective dose to the tumor. 
Therefore, IMRT offers a significant advantage over conventional radiotherapy. Nasopharynx 
is a site where IMRT can play a key role in improving the therapeutic ratio which can translate 
into better tumor control. Several studies have proved that IMRT results in improved survival 
in NPC along with reduced long term toxicities(23) (24) (25) (26) (27).  A high dose can be 
given to the nasopharynx while sparing critical normal structures such as the brainstem, the 
spinal cord, the optic chiasm, and salivary glands. 
At our institute, non-metastatic nasopharyngeal malignancies are treated with IMRT and we 
had employed the same for our study. 
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Lacunae in Current Knowledge and Need for Treatment Response Assessment  
 
Response prediction in Nasopharyngeal cancers is very essential as it helps in: 
DETECTING EARLY RELAPSES: Although NPC is very radiosensitive, in nearly 7%–
13% of cases residual disease persists after treatment(28). Moreover, the appearance of local 
or distant relapse determines a less favorable prognosis for these patients. Salvage treatment 
with radiosurgery or brachytherapy has been shown to give excellent tumor control in residual 
disease(29). Salvage surgery was also proved to achieve long-term survival in patients with 
local persistent or recurrent NPC who could achieve long-term survival(30). Thus, it is 
essential to be able to predict and monitor the therapeutic response of patients with NPC.  
 
After treatment, local findings of clinical examination may be unreliable as nasopharyngeal 
site is not completely accessible at clinical examination. The residual tumor may be sub-
mucosal making it unsuitable for biopsy. Moreover, CT imaging may be equivocal or 
inconclusive for detection of residual NPC due to the presence of diffuse soft-tissue 
inflammation and edema post radiation therapy at primary site which is often reported as 
merely an increase or decrease in soft tissue thickening. False-positive findings in CT 
regarding local persistence of disease detection are mainly correlated with inflammatory 
changes of the nasopharyngeal mucosa and sub mucosa. Nodal persistence also signifies a 
poorer prognosis if not detected and appropriately treated with salvage neck dissection. MR 
imaging is reported as more sensitive in depicting retropharyngeal lymph nodes(31),(32) which 
are the most frequent lymph node sites affected and not identifiable at clinical examination. 
Thus, CT imaging is inferior in detecting residual disease both at the primary site and neck 
nodal region in comparison to functional imaging modalities like PET/CT.  
37 
 
Functional imaging techniques using CT, MRI and positron emission tomography (PET) are 
increasingly being studied for the evaluation of tumors for staging, planning treatment 
volumes, assessment of response etc. These techniques exploit pathophysiological changes that 
occur within tumors such as altered blood flow, increased glucose metabolism, hypoxia and 
cellularity for tumor detection, monitoring of treatment response and to detect relapsed disease. 
1. TAILORED TREATMENT: The entire treatment strategy for locally advanced 
nasopharyngeal cancer has been majorly drawn from the Intergroup 0099 study. With time, 
the focus has shifted from ‘Cure alone’ to ‘Cure with better quality of life’. The intent of 
treatment is to achieve cure with least toxicities. Chen L et al. in a well conducted phase 3 
randomized trial, found that adjuvant cisplatin and 5 FU (Fluorouracil) chemotherapy did 
not significantly improve failure-free survival following concurrent chemoradiotherapy 
(33). In the current era, the whole concept of adjuvant chemotherapy is being questioned 
for those small cohorts of patients with complete response following chemoradiotherapy. 
This would potentially prevent physicians form unnecessarily subjecting those ‘Complete 
responders’ to adjuvant chemotherapy and its toxicities. This hypothesis however needs to 
be proven through a well conducted study. Before planning any study on de-escalation 
therapy, it is important to have: 
1. An accurate predictive tool for response evaluation to therapy 
2. Stringent follow up 
And our study is directed to find if Diffusion Weighted MRI is that predictive tool in question. 
Role of Functional Imaging Modalities in response assessment 
 
Various Functional imaging modalities have been described in literature, a few are described 
below: 
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1. Dynamic Contrast Enhanced Imaging 
2. Diffusion Weighted MR Imaging 
3. CT Perfusion Study  
4. FDG PET  
5. Bold Imaging 
6. Imaging in Hypoxia 
 
1.  Dynamic Contrast-enhanced Imaging 
Dynamic contrast-enhanced MR imaging is a non-invasive technique that helps characterize 
the microvasculature, thereby providing markers specific to perfusion, permeability of blood 
vessels, and the volume of extracellular space. 
Newbold et al demonstrated a statistically significant correlation between various dynamic 
contrast-enhanced MR imaging parameters, particularly Ktrans (which represents the 
permeability of blood vessels) and pimonidazole staining, an exogenous marker for 
hypoxia.(34) A pilot study done by Donaldson et al, supported the theory that more-hypoxic 
tumors have poorer vascular function, resulting in VEGF expression to increase blood flow to 
the tumor.(34) Hypoxia is known to limit the efficacy of radiotherapy and some chemotherapy 
agent. Non-invasive assessment of tumor micro vascularity with dynamic contrast-enhanced 
MR imaging could be incorporated in RT planning of Nasopharyngeal tumors, potentially 
allowing the selection of treatment strategies to combat radiation resistance associated with 
hypoxia. 
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2. Diffusion-weighted Magnetic Resonance Imaging (DW MRI) 
Diffusion-weighted MR imaging is also another non-invasive imaging technique that 
facilitates tissue characterization on the basis of the molecular motion of water molecules. 
Diffusion is quantified by using the Apparent Diffusion Coefficient values (ADC). The ADC 
is inversely correlated with cellularity meaning the more cellular the tumor is, lesser is the 
space for water molecule motion leading to its restriction for diffusion in the tumor tissue. This 
limited diffusion of water molecules in a very cellular tumor tissue is represented by a lower 
ADC value. Subsequently, with treatment as the tumor gets kills, it becomes less cellular and 
there is higher degree of diffusion of water molecules in the tumor tissue now which would be 
represented as increase in the ADC value.  
The increased density of cells within the primary tumor or malignant lymph nodes 
reduces their ADC at diffusion-weighted MR imaging.   
Study by Kim et al included 33 patients with head and neck SCCs, the change in ADC 
was used as a marker of tumor response 1 week after the commencement of chemoradiation 
therapy. Change in tumor ADC after 1 week of treatment had a high sensitivity and specificity 
for identifying patients who would have a partial or complete response to treatment. The pre-
treatment ADC value of complete responders was significantly lower (P < 0.05) than that from 
partial responders. A significant increase in ADC was observed in complete responders within 
1 week of treatment (P < 0.01), which remained high until the end of the treatment(37). Dirix 
et al evaluated the usefulness of diffusion-weighted MR imaging for radiation therapy planning 
and found that patients with local-regional recurrence had lower ADC values within the tumor 
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after 4 weeks of radiation therapy. This finding suggests that diffusion-weighted imaging 
would be useful for early identification of responders to treatment.(38) 
Multiple studies have been done in head and neck tumors evaluating the role of DW 
MRI as biomarker for response prediction and they had excluded Nasopharyngeal 
cancers(NPC). Hence there is a need for such studies in NPC.   
3. Perfusion CT 
Perfusion CT is based on the passage of iodinated contrast material through a region of 
interest to produce changes in attenuation, which may be used as markers of microvascular 
blood flow. A kinetic model analysis of these changes in attenuation allows the derivation of 
several physiologic parameters, including blood flow (BF) or perfusion, blood volume (BV), 
mean transit time (MTT), and permeability(39) 
              CT perfusion has been studied in patients with head and neck SCC for the diagnosis and 
characterization of disease and the prognostication and evaluation of its response to treatment. 
The development of new blood vessels (i.e. Neo-Angiogenesis), which is an adaptive response 
to hypoxia in the tumor, is an indirect marker that is demonstrated on perfusion CT as an 
increase in perfusion, BV, MTT, permeability, or a combination these. The results from 
numerous studies support the hypothesis that tumors with low perfusion have greater levels of 
hypoxia and therefore exhibit more resistance to treatment. 
4.  FDG PET: 
 FDG-PET imaging relies on transport of radiolabelled glucose into the cell, thus providing an 
indirect way of visualizing abnormal cells. 
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Treatment Response Assessment 
FDG-PET/CT can be used to assess treatment response in tumors, with most studies indicating 
that the efficacy of treatment not be assessed fully for at least 8–10 weeks after completion due 
to treatment (Chemotherapy or Radiation) induced inflammation. It is generally accepted that 
FDG-PET be performed 10–12 weeks after treatment completion to reduce the false-positives 
Evaluation for Residual or Recurrent Disease 
FDG-PET/CT is one of the most accurate non-invasive modalities presently available for 
differentiating posttreatment changes from residual or recurrent disease. While there may be 
false-positives (brown fat, asymmetric muscular activity, inflammation from infection or 
previous therapy) or false-negatives (small tumor size, low glycolytic activity), the sensitivity 
and specificity of FDG-PET/CT has been fair (85% and 91%, respectively) 
 
5. Blood Oxygen Level Dependent Imaging (BOLD Imaging) 
BOLD imaging, also known as intrinsic susceptibility–weighted MR imaging, is a functional 
imaging technique that is primarily used to evaluate brain activity triggered by exercise or 
other external stimuli. In recent years, it also has been used as a hypoxia-specific imaging 
technique. Contrast at BOLD imaging depends on the quantity of paramagnetic 
deoxyhaemoglobin within red blood cells, which generates an MR signal. BOLD uses a T2 -
sensitive sequence during oxygen inhalation to detect an increase in signal resulting from the 
reduced paramagnetic effect of a reduction in the blood deoxyhaemoglobin within a cancer. 
As with all functional MR techniques, BOLD presents challenges; the signal is not purely the 
result of oxygenation, the effects are short lived, and signal changes are small and may be 
difficult to reproduce.(40) However, despite these difficulties BOLD has been used 
successfully to detect decreases in the blood deoxyhaemoglobin in human cancers during 
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carbogen inhalation and shows promise for tailoring treatment for hypoxic cancers in the 
future. The use of BOLD MR imaging in patients with Nasopharyngeal cancer still under 
development, and further research must be performed before the technique may be validated 
and standardized to ensure reproducibility. 
6. Other Modalities of Hypoxia Imaging 
Hypoxia represents a negative prognostic factor for radiation treatment of Nasopharyngeal 
malignancies and is associated with significant resistance to chemoradiation. Hypoxic cells are 
resistant to cytotoxic effects of both chemotherapy and ionizing radiation. They require 
radiation doses much higher than those in the same cells under normoxic condition to achieve 
the same level of cell kill. Hence, there is growing need in diagnosing hypoxic areas before 
treatment in the hope of applying novel treatment strategies which might overcome resistance 
to conventional chemoradiation. 
Potential tumor hypoxia imaging agents include 18F-FMISO and copper 60 (II)-diacetyl-
bis(N4-methylthiosemicarbazone). 18F-FMISO is bound to cell constituents under hypoxic 
conditions with the level of hypoxia demonstrated by 18F-FMISO before treatment. Treating 
patients with hypoxic primary tumors with additional cytotoxin is expected to result in 
significantly lesser local failures than treating patients with chemotherapy alone. Biologic 
imaging for hypoxia detection can be crucial for prognostication and tailored therapy.  
Rationale for Choosing Diffusion Weighted MRI in our study  
 
 
1. GOOD ACCURACY WITH MRI  
As stated earlier, MRI is a better imaging modality than CT or PET in detecting tumor at 
primary site and retropharyngeal nodes(11). A study by Comoretto et al compared MRI and 
PET/CT in detecting residual/recurrent disease in 46 patients treated with chemoradiotherapy 
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in nasopharyngeal cancers(41). It concluded that MR demonstrated a trend toward higher 
accuracy than did FDG PET/CT (PPV of 87.1% Vs 85.2%, NPV of 96.9% Vs 86.1%, Overall 
accuracy of 92.1% Vs 85.7%) in depicting residual NPC at the primary tumor site and fairly 
well in detecting residual at nodal site (PPV of 83% Vs 95%, NPV of 95% Vs 97%, Overall 
accuracy of 91% Vs 96%).  
 
2. DWI MRI – MORE ECONOMIC  
Serial monitoring of response evaluation would need a minimum of imaging the patient thrice. 
PET would be much expensive compared to DWI MRI.  
Cost of different functional imaging in the institute where this study was conducted:  
PET CT – 3 x 22,000= Rs 66,000.00  
Functional MRI – 3 x 2265 =Rs 6,795.00  
MRI is cheaper with equivalent results as seen with PET.  
 
3. HIGH FALSE POSITIVITY WITH PET IN THE IMMEDIATE POST RT PERIOD  
PET imaging poses challenge during immediate post RT period, study performed too early 
may lead to false positive as well as false negative results. Post-treatment inflammation results 
in false positivity with resultant reduction in the specificity. Possible mechanism for false 
negative studies has been attributed to radiation induced vascular damage, which temporarily 
prevents concentration of radiotracer in the viable tumor cells(42). To strike a balance between 
misguiding PET results when study was done early and the drawbacks of imaging late, an 
interval of 12 weeks after completion of radiation is usually recommended. However, PET 
cannot be used for identifying complete response immediately following RT.  MRI would be 
a more reliable indicator of response evaluation.  
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4. BETTER TUMOR DELINIATION IN RADIOTHERAPY PLANNING  
MRI and PET CT images are often used to guide oncologist in delineating the tumor volume 
on the planning CT. However, tumor margins are indistinct on PET images because of 
movement, partial volume effects, and the lower spatial resolution of PET. The lesion 
appearance is influenced by the quality of the PET scanner, the reconstruction algorithm, and 
the image display threshold. Without standardization, apparent variations in tumor dimensions 
occur, making it difficult to ensure uniformity of contouring among different clinicians and 
facilities(43). MRI provides excellent soft tissue contrast resolution and helps in tumor and 
critical structure delineation for radiotherapy planning. 
Diffusion Weighted Magnetic Resonance Imaging – Biophysical basis 
 
Diffusion Weighted Imaging(DWI) explores the random motion of water molecules in the 
tissues. Water molecules are in a constant random movement called the Brownian motion. This 
uninhibited motion of water molecules is due to free diffusion. However, the movement of 
water molecules in tissues is restricted as their motion is limited ad modified by interactions 
with cellular membranes and macromolecules(44) 
 
The DWI signal in biologic tissues is derived from the motion of water molecules in the 
intracellular space, the extracellular space, and the intravascular space. The degree of 
restriction to water diffusion in biologic tissue is inversely correlated to the tissue cellularity 
and the integrity of cell membranes. The motion of water molecules is more restricted in tissues 
with a high cellular density associated with numerous intact cell membranes (e.g., tumor 
tissue). The lipophilic cell membranes act as barriers to motion of water molecules in both the 
extracellular and intracellular spaces. By contrast, in areas of low cellularity or where the 
cellular membrane has been breached, the motion of water molecules is less restricted. A less 
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cellular environment provides a larger extracellular space for diffusion of water molecules, and 
these molecules may also freely(45) 
 
 
Figure 8: Relationship between change in cellular density following an effective therapy and the 
corresponding distribution of water diffusion values within tumor. The mean diffusion value of 
tumor increases early following the loss of cellular density. 
 
Measuring Water Motion - Apparent Diffusion Coefficient (ADC) 
The moving water molecules acquire different phase information from the first gradient, but because 
of their motion, their signal will not be completely rephased by the second gradient, thus leading to 
a signal loss. Hence, the motion of water molecules is detected as attenuation of the measured signal 
intensity at DWI. The degree of water motion has been found to be proportional to the degree of 
signal attenuation. 
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The sensitivity of the DWI sequence to water motion can be varied by changing the gradient 
amplitude, the duration of the applied gradient, and the time interval between the paired 
gradients. On clinical MR scanners, the diffusion sensitivity is easily varied by changing the 
parameter known as the “b value,” which is proportional to these three factors. When the b 
value is changed, it is usually the gradient amplitude, rather than the duration or time intervals 
between gradients, that is altered. 
 
Treatment response assessment using Diffusion Weighted MRI 
 
Radiation therapy with chemotherapy as induction or concurrent or adjuvant is the standard of 
care for Carcinoma Nasopharynx. However, not all patients respond to chemoradiation 
therapy.  Thus, it is important to develop prognostic imaging biomarkers that can accurately 
predict treatment outcome before initiation of treatment. These imaging biomarkers may help 
in stratifying patients who would benefit from chemoradiation therapy from those who would 
not. With the use of Diffusion Weighted MRI (DW MRI), the ADC measurements will be able 
to predict the response of tumor to chemotherapy and radiation treatment 
 
Effective anticancer treatment results in tumor lysis, loss of cell membrane integrity, increased 
extracellular space, and, therefore, an increase in water diffusion. Impediments such as cell 
membranes, organelles, and macromolecules interferes with the free movement of water 
molecule, this diffusion in biological tissue is quantified by means of an APPARENT 
DIFFUSION COEFFICIENT (ADC). 
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With the use of Diffusion Weighted MRI (DW MRI), the ADC measurements will be able to 
predict the response of tumor to chemotherapy and radiation treatment. Two major factors in 
predicting response are: 
1. Baseline ADC values 
2. Magnitude of serial change in ADC values 
 
BASELINE ADC VALUES: Cellular tumor having low baseline ADC values respond better 
to chemotherapy or radiation treatment than tumors with high baseline ADC values. One 
possible explanation is that tumors with high baseline ADC values are likely to be more 
necrotic than those with low values. Necrotic tumors frequently are hypoxic, acidotic, and 
poorly perfused, leading to diminished sensitivity to chemotherapy and to radiation therapy. 
Studies in cerebral gliomas and breast cancers have also shown that an early increase in the 
ADC after commencing treatment was predictive of better treatment outcome.(46)  
 
MAGNITUDE OF SERIAL CHANGE: Diffusion weighted images with quantitative ADC 
(Apparent diffusion Coefficient) values have shown promise in predicting response to chemo 
radiation by assessing pre-treatment ADC values and monitoring their magnitude of change 
serially during treatment at different time frames. This diffusion restriction of water molecules 
can be assessed quantitatively by using ADC by obtaining two or more images with different 
gradient duration and amplitudes (which are referred to as different b values). 
             The term apparent refers to the dependence and modulation of these 
coefficients/diffusion processes on multiple factors in tissues such as restriction in closed 
spaces, tortuosity etc. ADC values are calculated automatically by the software and then 
displayed as a parametric map that reflects the degree of diffusion of water molecules through 
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different tissues. Then, by use of a dedicated workstation, ADC measurements are recorded 
for a given region by drawing regions of interest (ROIs) on the ADC map. An ADC of a tissue 
is expressed as a value in first decimal place x10-3 in units of mm2/sec (Eg: 1.1x10-3 
mm2/sec). 
                Rate of change of ADC values during the course of treatment have also been 
predictive of response to chemo radiation. Increase in ADC values as seen on subsequent scans 
with ongoing chemo radiation reflects treatment response as opposed to an inital rise followed 
by a fall in ADC values which would indicate no response to chemo radiation.  
              Hence at the start of treatment, tumors are anticipated to be densely cellular, posing a 
restricted diffusion with a diffusion histogram reflective of this. Shortly after initiation of the 
treatment, there is breakdown of cellular membranes, which is detectable with a rise in the 
ADC values.  Finally, after the completion of an effective treatment, tumor death leading to 
further breakdown of cells leading to a further rise in the ADC values. However, the poor or 
non-responders would not show any significant rise in the ADC values during the course of 
their treatment owing to the less cellular breakdown resulting in poor response to the treatment 
to Chemoradiotherapy. These tumors may show an initial rise in ADC values followed by a 
drop in the same. Thus, the serial monitoring of the ADC values at baseline, 1st week, 4th 
week and at 6 weeks follow up will help in correlating the ADC values of the responders and 
non-responders. If the ADC values are found to help in predicting treatment response, this 
valuable outcome could be utilized for tailoring the treatment care for this group of patients in 
the future. 
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Diffusion Weighted MR Imaging in Nasopharyngeal carcinoma: A Predictive Biomarker              
 
Studies conducted in squamous cell carcinoma of head and neck to establish DW MRI as 
predictive biomarker for response assessment have shown promising results. However, they 
have excluded Nasopharyngeal malignancies as it forms a distinct entity among the Head and 
Neck malignancies (37) (47) (48) (49). Studies on DW MRI in Carcinoma Nasopharynx are 
very limited. Two studies looked at response assessment using DWI-MRI in patients 
Carcinoma Nasopharynx undergoing chemoradiation. They had showed similar results as seen 
with other sites in Head and Neck suggesting the usefulness of DW MRI for response 
prediction in Nasopharynx. Jinsheng Hong, et al proved role of magnetic resonance diffusion-
weighted imaging in predicting radiosensitivity in NPC (50) (51). Guo-Yi Zhang et al. showed 
that pretreatment ADCs could be used as a new pretreatment imaging biomarker of response 
to neoadjuvant chemotherapy in nasopharyngeal malignancies (52).  
There has been no consensus as to an ideal follow-up time for imaging during and post 
chemoradiation. In a paper published on consensus of DWI imaging as a biomarker in cancers; 
it was emphasized that if DWI is used as a biomarker, imaging follow-up should be at a time 
before changes in size become appreciable (53). Study by King AD et al, showed that ADC 
post-treatment was a marker for local failure. Serial change in ADC was an even stronger 
marker (54) . Long term time frames may normalize ADC values as liquefactive necrosis 
resolves and becomes replaced by fibrosis. However, no uniform consensus has been 
formulated regarding an ideal time for follow. All patients routinely undergo a CT scan at the 
end of Chemoradiation (i.e. at 4- 6 weeks) to assess response to treatment. As the lesion may 
be sub mucosal, the NPL scopy may not show a growth. CT scan may show a response which 
may be reported as a decrease in the thickness in the nasopharyngeal region as well as a 
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reduction in the size of the nodes. An MRI with DWI and increase in ADC values may in turn 
give additional evidence of response.  
The eventual goal of this line of research is to use DW imaging and its parameters like ADC 
values at the various stages of treatment to prospectively identify patient who would benefit 
from concurrent chemoradiotherapy and classify them as responders and nonresponders. This 
valuable information can be further utilized for the modification of the treatment process, such 
as a boost of radiation therapy at the end of initial treatment, additional targeted therapies.  
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MATERIALS AND METHODS 
 
Place of study:  Christian Medical College, Vellore, Tamil Nadu, India 
Department Registry: Department of Radiotherapy in our Institute, on an average has 14-17 
patients of Carcinoma Nasopharynx treated per year 
Study Design:  Prospective Study 
Study Type:  Observational 
Inclusion Criteria: Patients with biopsy proven nonmetastatic carcinoma nasopharynx and 
fulfilling the following were be asked to enroll in the study after informed consent.  
1. Female or male patients aged 18-70 years  
2. ECOG Performance Status of 0 to 2  
3. Histologically confirmed carcinoma (Keratinizing, Non- keratinizing or Basaloid)  
4. Non- metastatic disease  
5. No previous chemotherapy or radiotherapy for any neoplasm/tumor  
6. Weight > 35kgs  
7. Adequate bone marrow function: WBC > 4000/mm3; Absolute Neutrophil count > 2000/cc 
platelets > 100,000 mm3  
8. Estimated creatinine clearance > 50ml/min/1.73m2  
9. Total bilirubin ≤ 1.5 times upper limit of normal (ULN), SGOT and SGPT ≤ 2 times ULN  
 
Exclusion Criteria:  
1. Presence of severe or uncontrolled systemic disease  
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2. Pregnant or breastfeeding mother  
3. Contraindication to MRI like MRI incompatible pacemaker / aneurysm clip  
Institutional Review Board Approval and Funding: 
Institutional Review Board (IRB) approval and fund grant was obtained prior to the 
commencement of the study (IRB No 10259 dated 05.09.2016) (attached in Appendix 4) 
Sample Size Calculation:  
The required sample size to show the proportion of response of about 80% with a precision 
of 15% was found to be 27 subjects who underwent chemoradiotherapy. However due to 
logistic issues and limited study period, we decided to include 20 patients. (Ref: Jinsheng 
Hong et al. Value of Magnetic Resonance Diffusion-Weighted Imaging for the prediction of 
Radiosensitivity in Nasopharyngeal Carcinoma. Otolaryngology – Head and Neck Surgery 
149(5) 707–713) with 95% confidence limits.  
Single Proportion - Absolute Precision  
Expected proportion      0.8  0.8 
Precision (%) 1     10  15 
Desired Confidence level (1- alpha) %   95  95 
Required sample size     61  27 
Formula: 
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Reference: Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of Sample Size in Health Studies. John Wiley and Sons, 1990. 
Sampling and Consent: The prospective study patients were seen in the outpatient department 
of Department of Radiotherapy, Christian Medical College Hospital from September 2016 to 
September 2017. All patients who fulfilled the inclusion criteria were included in the study.  
No specific sampling strategy was employed to enrol the patients.  The baseline data was 
entered in a numbered proforma (Annexure 3). Informed written consent was obtained from 
the patient/ patient relatives prior to the baseline diffusion weighted MRI imaging. The consent 
form along with the Patient Information Sheet is (attached in Annexure 1 and 2). 
Treatment Protocols:  Patients diagnosed to have Carcinoma Nasopharynx fulfilling the 
criteria were assessed based on the clinical examination findings Nasopharngolaryngeal scopy 
findings and a baseline CT scan and the suitable patients would be subjected to Diffusion 
weighted MRI imaging which is a non-invasive stud requiring less than 6 minutes to acquire a 
baseline ADC value. Subsequently the patients received their planned therapy with radical 
radiotherapy with 66-70 Gy in 33-35 fractions with concurrent 3 weekly Cisplatin spanning 
over 6 -7 weeks. As part of the study, ADC values were measured at baseline, 1 week, and 4-
6 weeks of follow up were compared and analysed for their changes to determine the response 
to the treatment. At 6 weeks follow up clinical examination, NPL Scopy and a follow up DW 
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MRI was repeated for evaluation of treatment response. Patients receiving induction 
chemotherapy were also included in the study. 
Data acquisition: MRI imaging was performed on a 3T Philips Achieva scanner with a neck 
coil. An axial T2HR sequence will be done in the neck from ventricles to clavicle with TE: 90; 
TR: 3500 and slice thickness of 5mm and slice gap of 5.6 mm. Matrix size used was 362 x 
292. DWI images were acquired with b values of 0 and 1000s/mm2 with slice thickness of 
5mm.  
Data analysis: ADC values are calculated automatically by the software and then displayed 
as a parametric map that reflects the degree of diffusion of water molecules through different 
tissues. Then, by use of a dedicated workstation, ADC measurements are recorded for a given 
region by drawing regions of interest (ROIs) on the ADC map. The DW MR and conventional 
T2-weighted images were reviewed by a senior radiologist. The radiologist blinded to the 
treatment outcome. Regions of interest (ROI) were placed on the primary lesions and target 
metastatic lymph nodes including most of the substantial area and avoid the necrotic area. 
Metastatic lymph nodes were chosen as per imaging criteria (a minimal axial diameter of 10 
mm threshold, including most of the substantial area and avoiding the necrotic area.  ADC 
values were calculated using different b-values, which measures the degree of diffusion 
weighting applied. A useful rule of thumb is to choose the b value such that (b X ADC) is 
nearly equal to 1. ADC values were derived from the ROI’s drawn over the metastatic nodes 
and tumor using a free handed drawn setting. Both mean and minimum ADC value were taken 
into consideration. The difference between Complete Response (CR) and Partial Response 
(PR)/ non- responders was assessed by Mann Whitney U test. ROC analysis was done to 
calculate predictive value of ADC as a marker to distinguish responders from nonresponders.  
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Outcome  
1. Primary Outcome: To study the role of diffusion weighted MRI derived parameters i.e. 
ADC as an imaging biomarker in non-metastatic nasopharyngeal carcinoma.  
2. Secondary Outcome/s: Validating the role of diffusion weighted in detection and 
characterization of nasopharyngeal cancers as well as for monitoring the response to 
CRT. 
 
 
Timing of DW MRI acquisition: 
A series of 3 diffusion weighted MRI scans were obtained serially at  
1. Pre- RT: Prior to initiation of radiotherapy 
2. Week 1: At 1 week after initiation of Radiation 
3. Follow Up: On 4-6 weeks follow up after Radiation 
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Detailed diagrammatic Algorithm of the study:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients diagnosed Non-Metastatic Nasopharyngeal malignancies recruited after 
biopsy, staging & informed consent 
Suitable for Radical Radiotherapy or Concurrent chemoradiotherapy  
Along with the baseline CT scan a DW MRI imaging is done to calculate the ADC 
value 
Initiation of treatment 
Baseline ADC vales compared with the serially monitored ADC values are 
measured at baseline(Pre-RT), at 1 week of RT and at 4 to 6 weeks follow up after 
RT 
Clinical examination, NPL Scopy/ RNE and a CT scan at 4 to 6 weeks after 
completing entire treatment including adjuvant chemotherapy (if any) for assessment 
of treatment response. 
No evidence of residual 
disease – Complete 
Responders  
Asymptomatic patient with 
doubtful significance of 
residual disease – Partial 
Responders 
Any evidence of residual 
disease then patient is 
categorized as -  Non-
responder 
Patient to be kept on 
follow 
Wait for 6 weeks more  
Repeat CT/PETCT to rule 
out the post radiotherapy 
changes 
Salvage therapy 
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RESULTS 
 
Social Demographics 
20 patients with histologically proven Carcinoma Nasopharynx were screened and 4 were 
excluded after reviewing the inclusion criteria. One patient had defaulted treatment. 2 other 
patients were enrolled into the study at the time of this write up, However, they were included 
for analysis. 13 were enrolled in this prospective study after informed consent. Pre-treatment 
diagnostic examinations included Endoscopy, biopsy and baseline contrast-enhanced CT in all 
patients.  
 
                                                               
 
 
                                                       
                                                                
                                                            
 
 
 
 
Flow chart: Consort diagram explaining the recruitment of patients for the study 
20 Patients with histologically diagnosed Carcinoma Nasopharynx 
were screened for the study 
4 Patients with Metastatic 
disease were excluded 
16 Patients meeting the inclusion criteria were invited to 
participate in the study 
1 Patient had not consented as 
she sought treatment at a 
different centre 
2 patients consenting for the 
study had just started treatment 
and had only baseline scan 
13 patients recruited in total had completed treatment 
3 are awaiting Follow up scan 
Total 10 patients were categorised for ADC study 
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Table 4: Baseline characteristics of patients in the study 
CHARACTERISTIC Category Number of patients  
1. Age 18 – 30 years 5 (38.4%) 
31 – 40 years 3 (23%) 
41 – 50 years  2 (15.3%) 
51 -  60 years  3 (23%) 
2. Sex Male 13 (100%) 
Female 0 
3. Comorbidities Diabetes  3 (23%) 
Hypertension 5 (38.4%) 
Nil comorbidities 7 (53.8%) 
4. Histology  Undifferentiated Non-Keratinizing 
Carcinoma 
9 (69.2%) 
Poorly differentiated Carcinoma 4 (30.7%) 
Basaloid 0 
5. T stage T1 2 (15.3%) 
T2 1 (7.6%) 
T3 5 (38.4%) 
T4 5 (38.4%) 
6. Node N0 0 
N1 4 (30.7%) 
N2 7 (53.8%) 
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N3 2(15.3%) 
7. Stage  Stage I 0 
Stage II 1 (7.6%) 
Stage III 5 (38.4%) 
Stage IV A 5 (38.4%) 
Stage IV B 2 (15.3%) 
8. Induction 
chemotherapy 
No Induction chemotherapy 4 (30.7%) 
3 Cycles of Docetaxel, Cisplatin and 
5 FU (DCF) 
7 (53.8%) 
3 Cycles of Cisplatin and Paclitaxel 2 (15.3%) 
9. Radiation therapy 
(Volumetric Arc 
Therapy with 
Simultaneous 
Integrated Boost) 
66 Gray in 33 fractions 1 (8%) 
70 Gray in 33 fractions 10 (76.9%) 
70 Gray in 35 fractions 2 (15.3%) 
10. Concurrent 
chemotherapy 
Cisplatin – 40mg/m2 
Weekly schedule 
2 (15.3%) 
Cisplatin – 100mg/m2 
Three Weekly schedule 
11 (84.6%) 
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Age and Sex distribution: 10 of 13 patients were below 50 years of age. 3 of them were in 
their 6th decade at the time of diagnosis. All thirteen patients were male. 
 
Figure 9: Frequency of Age distribution 
Majority of the patients were in stage III and IV A with 5 patients each. Two were of stage IV 
B and one had stage II disease. None of the patients were in stage I.  
 
Figure 10: Stage wise grouping of patients 
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Figure 11: T and N stage of the patients are summarized 
Induction Chemotherapy: Induction chemotherapy was given for 9 of 13 patients. Three of 
them were in stage III and six were in Non-Metastatic Stage IV (four in IVA and two in IVB. 
Seven out of nine patients received 3 cycles of three drug regimen (Triplet) with Docetaxel, 
Cisplatin and 5FU. Other two received 3 cycles of two drug regimen (Doublet) with Cisplatin 
and Paclitaxel. Age, comorbidities were taken in to consideration before choosing between the 
two Induction chemotherapy schedules. 
 
 
 
 
 
 
Figure 12a: Patients receiving induction therapy-Stage wise numbers b. Type of Induction 
chemotherapy 
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Radiation Schedules: The radical radiotherapy doses ranged from 66-70 Gy in 33-35 fractions 
using Volumetric Modulated Arc Therapy. Simultaneous Integrated Boost was employed for 
all patients. They were treated 5 days a week. Mean treatment duration was 7.2 weeks. All of 
them had completed radiation therapy by around 7 weeks with treatment break of less than 5 
days except 2 patients. One of them had a treatment break of 8 days due to grade 3 mucositis 
and completed RT by 8 weeks and other patient had defaulted treatment for 35 days due to 
personal reasons and completed RT by 12 weeks. 
 
 
 
 
 
 
 
 
 
Figure 13a: Pie chart depicting doses received by patients 
Figure 13b: Pie chart showing number of days of break in RT 
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Concurrent Chemotherapy: All patients received concurrent chemotherapy with 
Cisplatin(CDDP), the schedules followed were: 
1. 3-Weekly Cisplatin at 100mg/m2 given every 21 days (CDDP-100mg/m2) 
2. Weekly Cisplatin at 40mg/m2 given every 7 days (CDDP-40mg/m2) 
11 of 13 received 3 weekly schedules with 100 mg/m2 while the other 2 patients had weekly 
Cisplatin at 40mg/m2. 
 
 
 
 
 
 
 
 
 
Figure 14: A Doughnut pie chart depicting two different schedules of concurrent 
Cisplatin(CDDP) and number of patients in each. 
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Figure 15: Bar diagram showing Cumulative dose of Concurrent Cisplatin. 
X axis indicates total cumulative dose received, Y axis shows number of patients receiving it. 
 
 
Of the eleven patients who received 100 mg/m2 3-weekly Cisplatin, seven patients had 
completed two cycles, three patients had received one cycle and one patient had 3 cycles 
concurrently. Two patients with multiple comorbidities were planned for weekly Cisplatin with 
40 mg/m2 and both had received 4 cycles each concurrently.  
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Table 5: Overview of each patient’s treatment  
 
Patient 
No. 
Age / Sex Stage  Induction 
chemotherapy 
RTdose/Number 
of fractions 
Concurrent 
chemotherapy 
1 18/Male T3N1 No 66 Gy / 33 fractions 2 cycle of three 
weekly Cisplatin 
100mg/m2 
2 45/Male T3N2 No 70 Gy / 33 fractions 1 cycle of three 
weekly Cisplatin 
100mg/m2 
3 58/Male T4N1 No 70 Gy / 33 fractions 4 cycles of  
weekly Cisplatin 
40mg/m2 
4 20/Male T4N2 3cycles of 
Docetaxel, Cisplatin 
and 5FU 
70 Gy / 33 fractions 1 cycle of three 
weekly Cisplatin 
100mg/m2 
5 50/Male T1N1 No 70 Gy / 33 fractions 2 cycle of three 
weekly Cisplatin 
100mg/m2 
6 40/Male T3N3 3cycles of 
Docetaxel, Cisplatin 
and 5FU 
70 Gy / 33 fractions 2 cycle of three 
weekly Cisplatin 
100mg/m2 
 
Continued in next page 
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Patient 
No. 
Age / Sex Stage Induction 
chemotherapy 
RTdose/Number 
of fractions 
Concurrent 
chemotherapy 
7 38/Male T2N3 3cycles of 
Docetaxel, Cisplatin 
and 5FU 
70 Gy / 33 fractions 2 cycle of three 
weekly Cisplatin 
100mg/m2 
8 22/Male T3N1 3cycles of Cisplatin 
and Paclitaxel 
70 Gy / 33 fractions 2 cycle of three 
weekly Cisplatin 
100mg/m2 
9 57/Male T4N2 3cycles of Cisplatin 
and Paclitaxel 
70 Gy / 33 fractions 2 cycle of three 
weekly Cisplatin 
100mg/m2 
10 34/Male T4N2 3cycles of 
Docetaxel, Cisplatin 
and 5FU 
70 Gy / 35 fractions 4 cycles of  
weekly Cisplatin 
40mg/m2 
11 29/Male T1N2 3cycles of 
Docetaxel, Cisplatin 
and 5FU 
70 Gy / 33 fractions 3 cycles of  
three weekly 
Cisplatin 100/m2 
12 52/Male T3N2 3cycles of Cisplatin 
and Paclitaxel 
70 Gy / 35 fractions 1 cycle of three 
weekly Cisplatin 
100mg/m2 
13 18/Male T4N2 3cycles of 
Docetaxel, Cisplatin 
and 5FU 
70 Gy / 33 fractions 2 cycle of three 
weekly Cisplatin 
100mg/m2 
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The Diffusion-Weighted Imaging: All MR examinations were performed on a 1.5-T MRI 
machine. Conventional MRI was performed by using T2-weighted HR axial and diffusion 
weighted MR imaging. DWI was acquired in 5-6 minutes and ADC was calculated. DWI was 
performed at three-time points: Pre-radiation, Week one of radiation and on follow up at 6 
weeks after the end of treatment. At each assessment, DWI was performed on the same lesion, 
both for the primary site and the node. 
Image Analysis:  The ADC was measured on ADC maps by drawing a region of interest (ROI) 
around the largest area of solid tumour on a single slice identified with the aid of the T2-
weighted MR images. The ROIs were drawn by a radiologist blinded to treatment outcome. In 
addition, the ADC pattern over three-time points was evaluated for the trend with the mean 
and minimum ADC values to determine response was assessed. 
Statistical analysis:  Statistical analysis was performed by using SPSS software. ADC values 
Pre-RT, Week 1 and 6 weeks follow up were expressed as a mean and minimum with a 
standard deviation. The treatment response assessment was done by evaluating the changes 
seen in the ADC values. Analysis with ANOVA was done to compare the mean and minimum 
ADC values and correlation was derived between the Pre-RT ADC, Week 1 ADC and the 
follow up ADC for Mean and Minimum ADC values. Subsequently the sensitivity and 
specificity was assessed. Receiver operating characteristic curve (ROC) analysis was 
performed to determine the Mean and Minimum Pre-RT ADC value that best predicted 
locoregional failure. All statistical tests were two-sided, and p values less than 0.05 were 
considered statistically significant. 
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DWI – MRI OF COMPLETE RESPONDER: Primary lesion 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 17 A, B &C: T2 Weighted Imaging of the primary lesion of the same patient 
(Complete Responder) over the three-time periods 
 
 
 
A. Pre-RT                                         B. Week 1 of RT                               C. Follow up     
A. Pre-RT                                       B. Week 1 of RT                                  C. Follow up 
Figure 18 A, B & C: ADC map of primary lesion of the same patient (Complete 
Responder) over three-time periods  
 
 
Figure 16: CT Imaging of a Complete responder 
showing primary lesion at Diagnosis  
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DWI – MRI OF COMPLETE RESPONDER: Node  
 
 
 
 
 
 
 
 
 
 
 
 
 
AXAXAX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Pre-RT                                    B. Week 1 of RT                          C. Follow up  
Figure 20 A, B &C: T2 Weighted Imaging of the Node of the same patient (Complete 
Responder) over the three-time periods 
 
   
A. Pre-RT                                    B. Week 1 of RT                          C. Follow up  
Figure 21 A, B &C: ADC of the Node of the same patient (Complete Responder) over the three-
time periods 
 
 
Figure 19: CT scan of a Complete responder showing 
multiple level II nodes 
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DWI OF A PARTIAL RESPONDER: Primary 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
 
Figure 22: CT Imaging of a Partial 
responder showing primary lesion at 
Diagnosis  
 
A. Pre-RT                                     B. Week 1                                     C. Follow up 
A. Pre-RT                                     B. Week 1                                     C. Follow up 
Figure 23 A, B &C: T2 Weighted Imaging of the primary of the same patient (Partial 
Responder) over the three-time periods 
 
Figure 24 A, B &C: ADC map of the primary of the same patient (Partial Responder) over 
the three-time periods 
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DWI – MRI IN PARTIAL RESPONDER: Node 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
A. Pre-RT                                         B. Week 1 of RT                               C. Follow up     
A. Pre-RT                                       B. Week 1 of RT                                  C. Follow up 
Figure 27 A, B & C: ADC map of a Node of the same patient (Partial Responder) over three-
time periods  
 
 
Figure 25: CT image of a Partial responder 
showing right level II node 
Figure 26 A, B & C:  T2 Weighted Imaging of the primary of the same patient (Partial 
Responder) over the three-time periods 
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STACK DIAGRAM: 
 
 
 
 
 
 
 
Figure 28: Stack diagram showing Mean ADC distribution of our patient cohort 
This stack graph is representative of the Mean ADC distribution of our patient cohort. In our 
study group patient 8 and 9 did not have Week 1 Imaging due to technical issues and hence the 
ADC couldnot be calculated at these timepoints. All the 13 patients, an increasing trend in the 
ADC values at three different time points was observed. Patient 10, 12 and 13 had just 
completed treatmet at the time of analysis  and their follow up scans were awaited. Hence we 
analyssed with total of 10 patients. They were categorised at the end of the treatmet as 
Completed Responders and Partial Responders based on clinical, Endoscopy or CT scan 
findings. 
COMPLETE RESPONDERS PARTIAL RESPONDERS 
5 patients 5 patients 
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Complete Responders: The absence of any residual lesion on clinical examination, 
Endoscopy (Rigid nasal endoscope) or by CT scan was defined as complete response.  
 
 
 
 
 
 
 
 
Figure 29: Bar diagram representing rise in MEAN ADC values for COMPLETE 
RESPONDERS for both Primary and the Node. ADC values in: (x 10-3 mm2/s) 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Bar diagram representing rise in MINIMUM ADC values for COMPLETE 
RESPONDERS for both Primary and the Node. ADC values in: (x 10-3 mm2/s) 
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Complete Responders: The study of the general trend of the mean and minimum ADC 
variation in these subset of patients revealed an increase in the ADC values among the 
subsequent dWMR imaging. In our study, 5 patients had complete response by 6 weeks follow 
up. Among these 5 patients, the Week 1 DWI-MRI did not show any visible disease for 4 
patients. 
Visual Restriction: The diffusion restriction as seen on ADC map is termed Visual restriction. 
It is a qualitative expression of diffusion restriction. We had used visual restriction for 
Response predication. We found that the 4 patients in complete responder had  no visual 
restriction on the ADC mapping at Week 1 DWI-MRI. 
Impact of Stage, Histology, Radiation and Chemotherapy: Three patients belonged to 
Undifferentiated histology. Two out of five patients were in Stage IVA with poorly 
differentiated histology. All 5 had received RT doses of 70 Gy. Only two had induction 
chemotherapy 
Patient 
no.  
Stage  Histology Radiation doses Induction chemotherapy 
2 III Undifferentiated 70 Gy / 33 # No 
3 IV A Poorly differentiated 70 Gy / 33 # No 
4 IV A Poorly differentiated 70 Gy / 33 # 3 Cycles of Docetaxel, 
Cisplatin and 5 FU (DCF) 
5 II Undifferentiated 70 Gy / 33 # No 
11 III Undifferentiated 70 Gy / 33 # 3 Cycles of Docetaxel, 
Cisplatin and 5 FU (DCF) 
 Table 6: Overview of treatment and patient factors in complete responders 
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Partial Responders: The presence of any residual lesion on clinical examination, 
Endoscopy(RNE) or by CT scan was defined as partial response. 
 
 
 
 
 
 
 
 
 
 
Figure 31: Bar diagram representing rise in MEAN ADC values for PARTIAL RESPONDERS 
for both Primary and the Node. ADC values in: (x 10-3 mm2/s) 
 
 
 
 
 
 
 
 
 
 
Figure 32: Bar diagram representing rise in MIMIMUM ADC values for PARTIAL 
RESPONDERS for both Primary and the Node. ADC values in: (x 10-3 mm2/s) 
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Partial Responders:  
In our study, 5 patients had residual disease by 6 weeks follow up. The study of the general 
trend of the mean and minimum ADC variation in  partial responders also had revealed an 
increase in the ADC values among the subsequent DWI-MR imaging. Among these 5 patients, 
the Week 1 DWI-MRI had shown residual disease for 3 patients. 
 
Visual Restriction: Visual restricted was used for partial responers for response prediction. 
Visual restriction was present for primary for 3 and all 5 of them at visual restriction at node 
on ADC mapping on DWI-MRI at Week 1.  
 
Impact of Stage, Histology, Radiation and Chemotherapy: There were 3 patients with 
Undifferentiated histology and 1 with Poorly differentiated histology. Two of them had N3 
disease putting them in stage IV B. Two patients were in stage III and the other one was stage 
III. Four out of five patients received induction chemotherapy except one. Four had received 
RT doses of 70 Gy. Only one patient who had received 66 Gy in the study was found to have 
residual at primary.  
 
Correlation of response with Other modalities: Patients categorised as partial responder also 
had either PET-CT or biopsy of the residual to validate the results and they were depicted in 
table 7. Three patients who were classified as Partial responders also had proven residual on 
PET-CT and two other patients were false positives. 
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False Positives:  
1. Patient 8 : This patient was  found to have a residiual node as on clinical examination 
at follow up.  MRI and CT performed had releaved residual at right level II which had 
increased in size as compared to Pre-RT. His case was discussed in Multidiscplinary 
tumoe board and he underwent salvage neck dissection as per decision. Histopathology 
was reported as necrotisng granulomatous inflammation with acid fast bacilli suggestive 
of Tuberculous lymphadenitis and was started on antituberculosis therapy (ATT) soon 
after that.  
 
2. Patient 9 : This patient had residual at primary site on rigid nasal endoscopy. Biopsy 
from the site reported chronic inflammation. On CT, he was found to have extensive 
infective ethmoidal and maxillary sinsitis . He underwent FESS for the same.  
 
 
We had inferred that conditions like tuberculous lymphadenitis would mimic residual at nodal 
site. Also infective conditions of the surronding structures in the region of Nasopharynx would 
lead to the suspicion of recurrence. These would have a bearing on our study as these patients 
in real sense were responders to therapy who were classeifed as Partial responders based on 
RNE, Clinical and CT findings.  
 
We suggest confirmation by biopsy remains the gold standard  for diagnosing residual disease 
as these would result in a false positive result. 
Table 7 continued in next page  
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Table 7: Overview of treatment and patient factors in partial responders 
Patient   Stage  Histology Radiation 
doses 
Induction 
chemo 
Site of 
failure 
on DWI-
MRI 
Residual 
on as 
seen on 
PET-CT 
Biopsy 
1 III Undifferentiated 66 Gy / 33 
# 
No Primary Primary No biospy 
6 IV B Undifferentiated 70 Gy / 33 
# 
3 Cycles 
of DCF 
Node Node  No biopsy 
7 IV B Poorly 
differentiated 
70 Gy / 33 
# 
3 Cycles 
of DCF 
Primary  
& 
 Node 
Priamry 
& 
Node 
No biopsy 
8 III Undifferentiated 70 Gy / 33 
# 
3 Cycles 
of DCF 
Node No PET Necrotising 
granulomatous 
inflammation 
postivie for 
acid fast 
bacilli 
9 IV A Poorly 
differentiated 
70 Gy / 33 
# 
3 Cycles 
of DCF 
Primary No PET Necrosis with 
Chromic 
inflammation, 
artefacts 
present. 
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Complete Responder Vs Partial Responder 
1. Mean Baseline ADC: Correlation was made between the Mean Pre-RT ADC and the 
nature of response obtained. The Mean ADC values were higher for Complete 
responders for the minimum, maximum and median values. In the primary lesion, the 
complete responders had a minimum Pre-RT ADC of 0.8x10-3 and a maximum of 
1.2x10-3. When compared to the partial responders in whom the mean Pre-RT ADC 
values ranged from 0.7x10-3 to 0.8x10-3 as seen in the table below. Similarly, for the 
node, the Pre-RT ADC values were higher for complete responder than Partial 
responder in terms of minimum, maximum and median values. 
PRIMARY 
TUMOR 
Minimum Pre-RT 
ADC (In mm2/s) 
Median Pre-RT ADC 
(In mm2/s) 
Maximum Pre-RT 
ADC (In mm2/s)  
Complete 
Responders 
0.8 x 10-3 1 x 10-3 1.2 x10-3 
Partial Responders 0.7 x 10-3 0.8 x 10-3 1.1 x 10-3 
 
NODE Minimum Pre-RT 
ADC (In mm2/s) 
Median Pre-RT ADC 
(In mm2/s) 
Maximum Pre-RT 
ADC (In mm2/s) 
Complete 
Responders 
0.6 x 10-3 1 x 10-3 1.3 x 10-3 
Partial 
Responders 
0.4 x 10-3 0.6 x10-3 1.1 x10-3 
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2. Visual Restriction: The diffusion restriction as seen on ADC map is termed Visual 
restriction. It is a qualitative expression of diffusion restriction. We had used visual 
restriction for Response predication. We found that the 4 patients in complete responder 
had  no visual restriction on the ADC mapping at Week 1 DWI-MRI. Whereas in Partial 
Respnders, Visual restriction was present for primary for 3 and all 5 of them at visual 
restriction at node. This proves that Visual restriction has the potential to predict 
reposnse to treatment as early as 1 week. 
 
 
 
 
 
 
 
 
 
Figure 33: Cross table showing presence or absence of Visual restriction of primary tumor on 
ADC map of DWI-MRI at Week 1 and its correlation with response assessment (p value: 0.6) 
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3. Rate of change in ADC values  
 
A. Box plot comparing Mean ADC value of complete responders and partial responders 
over the three-time points for PRIMARY TUMOR
 
BOX PLOT comparing Mean ADC value of complete responders and partial 
responders – PRIMARY TUMOR 
BOX PLOT comparing Mean ADC value of complete responders and partial 
responders – PRIMARY TUMOR 
BOX PLOT comparing Mean ADC value of complete responders and partial  
 
 
 
Box plot 1: This Box plot compares the Mean ADC values of primary tumor in Complete 
Responders and Partial responders over the different time points (Pre-RT, Week 1 and 
Follow up). ADC in (10-3 mm2 /sec) 
 
The complete responders had a higher mean ADC values at baseline (Pre-RT) compared to 
partial responder. Among partial responder patient 7 had a high increase in mean ADC by 
Week 1 and thus remained an outlier in the box plot. Hence at week 1, the partial responder 
box plot had the highest mean value because of the plot appear at a higher level for partial 
responders. Otherwise, complete responders had a greater rise in mean ADC values with 
radiation in comparison to partial responders at follow up. 
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B. Box plot comparing MINIMUM ADC value of complete responders and partial 
responders over the three-time points for PRIMARY 
 
 
 
 
 
 
 
 
 
 
Box plot 2: This Box plot compares the Minimum ADC values of primary tumor in 
Complete Responders and Partial responders over the different time points (Pre-RT, 
Week 1 and Follow up). ADC in (10-3 mm2 /sec) 
 
The complete responders had a higher Minimum ADC values at baseline (Pre-RT) 
compared to partial responder. Also, complete responders had a greater rise in 
Minimum ADC values with radiation in comparison to partial responders at all time 
points 
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C. Box plot comparing MINIMUM ADC values of complete responders and partial 
responders over the three-time points for NODE 
 
 
 
 
 
 
 
 
 
 
Box plot 3: This box plot compares the Minimum ADC values of Node in Complete 
Responders and Partial responders over the different time points (Pre-RT, Week 1 and 
Follow up). ADC in (10-3 mm2 /sec) 
 
The complete responders had higher minimum Pre-RT ADC values compared to partial 
responder. The rate of increase in Minimum ADC values over three-time points was 
greater among complete responders in comparison to partial responders at all time points 
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D. Line graph comparing complete responders and partial responders – TUMOR 
 
 
Line graph1: The lines depicting change in mean ADC values over three-time points for 
complete responders (Orange line) and partial responders (Blue line) were seen crossing each 
other at week 1. This was due to patient 7 in the partial responder category had a very high 
increase in mean ADC by Week 1 and thus was an outlier. This had led to increase in 
average mean ADC for partial responder resulting in an erroneous interpretation of this line 
graph. However, at follow up the complete responder had a higher rise in ADC values than 
partial responders (ADC in 10-3 mm2 /sec) 
 
 
Line graph2: The rate of increase in Minimum ADC values over three-time points was 
greater among complete responders in comparison to partial responders at all time points 
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E. Line graph comparing complete responders and partial responders – NODE 
 
 
Line graph 3: This line graph shows the change in Mean ADC values over three-time 
points was greater for Complete Responders than Partial Responders in the node. ADC 
in (10-3 mm2 /sec) 
 
 
 
Line graph 4: This line graph shows the minimum ADC(ADCmin) values for Complete 
Responders and Partial Responders was well separated with higher increase in ADCmin 
over time in the node.  
ADC in (10-3 mm2 /sec) 
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F. Difference in Minimum ADC between Pre-RT and Week 1 (ADCmin12) 
 
 
 
 
 
 
 
 
 
 
 
 
G. Difference in Minimum ADC between Pre-RT and follow up (ADCmin13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box Plot 4: The 
difference between 
Pre-RT minimum 
ADC and Week 1 
ADC (ADCmin12) 
was greater among 
Complete 
Responder. 
However, the p 
value was not 
significant 
Box Plot 5: The 
difference between 
Pre-RT minimum 
ADC and Follow 
up ADC i.e. 
(ADCmin13) was 
greater among 
Complete 
Responders in 
node.  
The p value was 
significant  
(p = 0.03) 
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Correlations: 
1. Correlation of Mean Pre-RT ADC and Week 1 ADC  
 
  
 Figure 34: Non-Parametric tests showing correlation between ADC over different time 
periods 
 
 
 
 
 
 
 
 
 
 
We had also looked at Correlation between mean Pre-RT ADC, Week 1 ADC and 
follow up ADC. It showed positive correlation for Mean Pre-RT with Mean Week 1 
ADC in complete responders. 
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2. Correlation between Primary tumor size and mean ADC value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scatter plot 1: This plot shows Negative correlation between primary tumor size and ADC 
value. This means that greater the tumor size lesser is the mean ADC value suggestive greater 
possibility of being a partial responder.  
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Sensitivity and Specificity 
  
1. Pre-RT mean ADC 
 
Figure 35: ROC log regression analysis table with Sensitivity and Specificity determining 
tables- log regression analysis for Mean Pre-RT ADC values 
 
Based on the ROC curve, the sensitivity and specificity of the Pre-RT mean ADC to determine 
the treatment response was assessed which revealed a sensitivity of about 80% and a specificity 
of about 60%. The rest of the sensitivity and specificity could be determined from the table 
above 
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2. Pre-RT minimum ADC  
 
  
Figure 36: ROC log regression analysis table with Sensitivity and Specificity determining 
tables- log regression analysis for Minimum Pre-RT ADC values 
 
The primary objective of this study was to determine a correlation between the Pre-RT ADC 
and the prediction of treatment response. Based on the ROC curve the sensitivity and 
specificity of the Pre-RT minimum ADC to determine the treatment response was assessed 
which revealed a sensitivity of about 80% and a specificity of about 80%. The rest of the 
sensitivity and specificity could be determined from the table above.  
 
 
 
 
 
 
91 
 
DISCUSSION  
 
In this study, we investigated the role of ADC for prediction and early detection of treatment 
response to chemoradiation therapy in Nasopharyngeal Carcinoma. The ADC values at various 
time points were calculated and were correlated with treatment response.  
Patient population: The patient population in our study were predominantly stage III and non-
metastatic stage IV, similar to other trials which also had the majority of patients in the locally 
advanced stage. The median age in our study was 40 years was also in concurrence with other 
studies. A male predilection was seen in all studies, and our study had all male patients.   
Induction chemotherapy: There has been an increasingly growing evidence for Induction 
chemotherapy with platinum-based agents. In a pooled analysis, induction chemotherapy was 
found to have decreased relapse and increase in disease-specific survival (55)  Studies 
conducted for prediction of response assessment to treatment using DWI in Nasopharyngeal 
carcinoma had the majority of patients receiving Induction chemotherapy. Our study also had 
70% of patients receiving platinum-based induction chemotherapy. 
Radiation therapy: All patients had radiation delivered by Volumetric Modulated Arc 
Therapy(VMAT) using Simultaneous Integrated Boost technique (SIB). Doses ranged from 
66-70 Gy in 33-35 fractions as seen with other studies. All patients received 70Gy except 
patient 1 in our cohort, who received 66 Gy and he had residual disease at first follow up and 
was further categorized as a partial responder. 
Concurrent chemotherapy: All our study patients had received concurrent Cisplatin. Patients 
in this study had treatment was in concurrence with the standard of care for Carcinoma 
Nasopharynx (17) 
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Data acquisition: The imaging protocols and measuring ADC values were as described in our 
methods were similar to two other studies - Chen et al. and J Hong et al. (50) (51). We 
contoured regions of interest with free hand technique and made sure the necrotic regions were 
avoided as they tend to have an abnormally high ADC due to free water movement. This could 
result in erroneous results.  
 
Results: We found that two major factors predicting response were: 
1. Difference in serial ADC values  
2. Pre-RT ADC 
The difference in serial ADC values: 
Studies by Chen et al. and Hong et al. also found that change in mean ADC was independent 
factor in predicting response to chemoradiation in carcinoma Nasopharynx. Though our study 
showed greater difference of mean ADC for Complete responders in comparison to Partial 
responders, it was not statistically significant. The difference between Pre-RT minimum ADC 
and Follow up ADC was greater among Complete Responders. The p-value was significant. 
(p = 0.03). We inferred that ADC minimum value represents an area of densely packed tumor 
tissue and possibly could be the more radio resistant region with in the tumor. We feel it is 
more prudent to consider minimum ADC values along with mean ADC values form the region 
of interest. To our knowledge, we are the first to find Minimum ADC to be more sensitive than 
Mean ADC. 
 This can have clinical utility in dose painting in that it could use these areas of minimum ADC 
and visual restriction for dose escalation. Also, regions with a very high ADC are seen within 
necrotic areas which could also be treated to a higher dose 
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Comparison with other studies: 
 YunBin Chen et al. Jinsheng Hong et 
al. 
Current study 
No of patients, n 31 121 13 (10 analysed) 
Stage  Stage III and IV 
(Non-metastatic) 
All stages  All stages 
(Non-metastatic) 
DWI-MRI time 
points 
1. Baseline 
2. Day 3 post chemo 
3. Day 20, post 
chemo 
4. Day 50, 6 days 
after RT 
5. At completion of 
chemoRT 
1. Baseline 
2. Week 2 after 
initiation of 
RT 
3. Follow up at 
3 months 
1. Pre-Radiation 
2. Week 1 after 
initiation of 
RT 
3. Follow up at 
6 weeks 
Induction 
chemotherapy 
All received platinum 
based chemotherapy (2-4 
cycles) 
Platinum based 
chemotherapy (80% 
received chemo) 
9 (69.2%) patients 
had 3 cycles of 
platinum based 
chemotherapy 
RT doses 70 Gy in 35 fractions 66 -74 Gy in 30 to 
33 fractions 
70 Gy in 33-35 
fractions (66 Gy for 
2 patients) 
Concurrent 
chemotherapy 
67% received concurrent 
chemotherapy 
- 3 weekly Cisplatin 
100mg/m2 (21) 
- Immunotherapy (2) 
60% patients 
received 
chemotherapy 
- Cisplatin – 80 
mg three 
weekly  
All received 
concurrent chemo 
- Three weekly 
Cisplatin 
(85%) 
- Weekly 
Cisplatin 
(15%) 
Results Change in mean ADC 
from Baseline to Day 20 
is significant for 
Response prediction 
(p = 0.017) 
Change in mean 
ADC from Baseline 
to Week 2 is 
significant for 
Response prediction 
(p = 0.002) 
Change of 
difference in 
Minimum ADC 
difference from Pre-
RT to Follow up is 
significant for 
Response prediction 
(p = 0.03) 
Table 10: This table shows comparison of our data with similarly conducted studies 
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Response prediction with Pre-RT ADC: In our study, the ADC variation observed were as 
follows across the complete responders and partial responders 
PRIMARY 
TUMOR 
Minimum Pre-RT 
ADC (In mm2/s) 
Median Pre-RT 
ADC (In mm2/s) 
Maximum Pre-RT 
ADC (In mm2/s) 
Complete 
Responders 
0.8 x 10-3 1 x 10-3 1.2 x 10-3 
Partial Responders 0.7 x 10-3 0.8 x 10-3 1.1 x 10-3 
 
Similar finding was observed for metastatic cervical nodes as well. However, the p values were 
not significant. 
NODE Minimum Pre-RT 
ADC (In mm2/s) 
Median Pre-RT ADC 
(In mm2/s) 
Maximum Pre-RT 
ADC (In mm2/s) 
Complete 
Responders 
0.6 x 10-3 1 x 10-3 1.3 x 10-3 
Partial 
Responders 
0.4 x 10-3 0.6 x10-3  1.1 x 10-3 
 
This finding is in unison with the study by Zheng. D et al. who had compared the mean ADC 
values (lowest, highest and average) of complete responders and partial responders.(56) They 
found Mean ADC in effective groups was significantly (P < 0.05) higher than that in the 
ineffective group. Average and minimum ADC demonstrated higher sensitivity than maximum 
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ADC for predicting response to treatment. The sensitivity and the specificity for Pre-RT mean 
ADC value to predict response was 80% and 60% respectively. 
Similarly, the calculated sensitivity was 80%, and the specificity was also 80% for Pre-RT 
minimum ADC value to predict response.
 
Figure 37: Zheng. D et al: The average, minimum and maximum ADC values in their study 
and its significance in predicting response to treatment. 
 
Our study showed that patients with high Mean and Minimum ADC showed a trend towards 
complete response with a reasonable sensitivity and specificity. However, the p-value was not 
significant. From the observations made from our study we recalculated sample size required 
to prove significance. 
 
Using ADCmin, we need 19 patients in either of complete responder or partial responders 
group, to find significance. This would require studying at least 40 patients. And using Mean 
ADC, it is 419 patients in each group.  
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We are continuing the study to reach the required sample size for proving significance for 
Minimum ADC. 
Problems with sample size: As explained earlier, of the 20 patients screened 4 were excluded 
as they had metastatic disease. One did not consent to participate in the study.  T two patients 
had only started treatment at the time of this analysis, and only Pre-RT MRI was available and 
therefore were not included. Of the thirteen patient who had completed treatment, 2 had 
completed treatment in last week of September 2017 and hence were awaiting at the 6 weeks 
follow up scan. One patient from overseas did not return for follow after completing 
chemoradiotherapy and is continuing his further treatment in his home country.  Hence, we 
had only 10 patients for complete analysis.  
LIMITATIONS OF THE STUDY 
 
1. Short Study Period: This study was done as a part of requirement for a 2-year 
MD dissertation and therefore there was a difficulty in accruing the number 
planned at the outset of the study. There were eligible patients but who could not 
be recruited into the study for reasons mentioned before. This simulates real life 
situation which we encounter every day in our clinics while trying to conduct 
clinical trials. However, we plan to continue recruiting patients to reach the 
calculated sample size. This will enable us to draw a meaningful conclusion at 
the end of the study, and we hope to present the findings at a scientific conference 
and publish in a scientific journal as we feel these findings are clinically 
significant and will add to the limited literature available on this subject.  
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Although we could prove our hypothesis that Diffusion Weighted Imaging plays 
a key role in the prediction of early treatment response in patients diagnosed with 
Carcinoma Nasopharynx, we need a larger sample size to yield a better outcome.  
2. Short Follow Up: The study patients need to be followed up for longer period of 
time to establish role of Diffusion-weighted imaging in predicting long term 
disease control.  
3. False Positive: One patient classified as a partial responder with persisting neck 
node was found to have T.B Lymphadenitis after salvage neck dissection. 
Another patient was suspected to have residual primary had Maxillary and 
Ethmoidal sinusitis. 
FUTURE DIRECTIONS 
 
1. Dose Painting using DWI-MRI: Radiotherapy treatment planning incorporating DWI-
MRI may a tool of the future for dose painting and radiotherapy dose escalation. This 
modality may aid in identifying and contouring necrotic areas and the diffusion 
restricted areas. This may eventually help in better tumor control and thus translates 
into a superior locoregional control and survival.  
 
2. Biological Adaptive Radiotherapy (BiGART): With the introduction of MR-LINAC 
(MRI Linear Accelerator) for clinical use, the possibility of incorporating DW imaging 
may find its utility in Adaptive Radiotherapy using Biological Imaging. 
 
3. De-escalating therapy in Complete responders: With evidence from studies showing no 
improved failure-free survival from adjuvant chemotherapy following concurrent 
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chemoradiotherapy in Carcinoma Nasopharynx, there is an increase in the need to 
develop a tool to predict response to concurrent chemoradiation before omitting it and 
thereby reducing treatment related toxicity (33). We feel that DWI-MRI may be an 
additional tool to aid in response assessment and de-scalation of therapy. 
CONCLUSIONS 
 
• Serial DWI-MRI is a potential tool for response prediction in carcinoma nasopharynx 
treated with chemoradiotherapy.  
• Quantitatively, the difference in Minimum ADC values from baseline to follow up was 
statistically significant to predict response to chemoradiation. 
• Qualitatively, Visual diffusion restriction is a potential tool to explore in DWI-MRI for 
response prediction. 
• Mean and Minimum Pre-RT values could predict response.  
• This study needs to be continued and a larger sample size and long term follow up may 
help in establishing its role in clinical practice.  
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ANNEXURES  
 
Annexure 1 : Patient Information  
  
Department of Radiotherapy 
CMC Hospital Vellore, Tamil Nadu Informed Consent Sheet No.............. 
 
Title of Research –`` To study the role of diffusion weighted MRI in predicting response to 
concurrent chemoradiotherapy / neoadjuvant chemotherapy in nasopharyngeal malignancies 
`` 
Person carrying out the research: Dr ------------- 
 
Part I: - Information sheet 
 
Introduction- I am Koti Krishna Amulya, post graduate student in the department of 
Radiotherapy. I am doing a research on predicting response to preoperative 
chemoradiotherapy in patients diagnosed with non metastatic nasopharyngeal cancer with the 
help of the special MRI imaging during the course of your treatment. I am going to give you 
the information regarding my study and invite you to be a part it. At any point of time if there 
is any doubt or you are not clear with the study protocol please feel free to ask. 
Purpose of the research: All patients with nasopharyngeal cancers similar to your type of 
cancer, are treated with radical chemoradiation/ neoadjuvant chemotherapy followed by 
chemoradiation - which is the standard treatment option. Shortly after initiation of the 
treatment, there is breakdown of tumour cells, which is detectable on the special MRI 
imaging. However the non responders to chemoradiotherapy will have less cellular 
breakdown as a result of the poor response to the treatment with chemoradiotherapy. Thus in 
my study with the help of repeated special MRI imaging at baseline ,1 week and at 
completion of chemoradiation patients and by correlating with the postop sample are 
categorized as responders(those patients responding to chemoradiotherapy) and non 
responders( patients not responding to chemoradiotherapy). This valuable outcome can be 
utilized for tailoring the treatment care for the select group of patients in future. 
 
Participant Selection: You have been invited to participate in this study because you have 
been diagnosed to have nasopharyngeal cancer and through this study we will be able to 
predict your treatment response to the preoperative chemoradiotherapy with the help of the 
series of special MRI imaging. 
 
Voluntary participation: Your participation in this research is entirely voluntary. It is your 
choice to participate or not. Whether you choose to participate or not, your management does 
not change at all. You may even change your mind and withdraw even if you had agreed 
earlier. 
Information on the Research study: All patients who have been selected for the study –ie 
the patients diagnosed with nasopharyngeal cancer planned for preoperative 
chemoradiotherapy. A series of special MRI imaging at baseline, 1st week, and 
completion of chemoradiotherapy would be done. The imaging study would just take 6 
minutes in all and would be well coordinated with the Department of Radiology for your 
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convenience without much waiting time. With this study we will be able to categorize you as 
responders and non responders to the current treatment of choice of radical 
chemoradiotherapy. This valuable information would be useful as a practise changing trend 
in tailoring the treatment patients diagnosed with locally advanced carcinoma esophagus. 
The series of special imaging would be provided free of cost for you. 
 
Side effects: This is an observational study posing no harm to the patients. This special form 
of imaging is a non invasive procedure with absolutely no side effects. 
 
Risks: Being an observational study it poses no risks to the patients. 
 
Benefits: Categorizing the patients as responders and non responders does not warrant any 
change in the management of the select group of patients. However the results of this study 
would help in the validation of the role of diffusion weighted MRI study in predicting the 
treatment response in a similar group of patients in the future and to tailor their treatments 
based on their ADC values. 
 
Confidentiality: Your name will not be mentioned anywhere in the data sheet or the final 
published study. Your data will bear a study number and the same number will be used till 
analysis. 
 
Sharing of the result: The result of research is the property of Christian Medical College 
and I am entitled to publish it in a journal or at a conference. 
 
Right to refuse or withdraw: You do not have to participate in this research if you do not 
wish to. It is your choice and all your rights will be respected. This study has been reviewed 
by [IRB, Christian Medical College], which is a committee whose task is to 
make sure that research participants are protected from harm. If you wish to find more about 
the IRB 
 
 
Contact 
Institutional Review Board, 
Christian Medical College 
Office of Research, I st Floor, Carman Block, Bagayam, Vellore 632 002 India. 
E-mail: research@cmcvellore.ac.in. 
Tel: 0416 -2284294, 2284202 Fax: 0416 – 2262788, 2284481. 
It has also been reviewed by the Ethics Review Committee CMC Vellore, which is 
supporting the 
study. 
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Annexure 2: Certificate of Consent 
 
Title of Research –`` To study the role of diffusion weighted MRI in predicting response to 
concurrent chemoradiotherapy / neoadjuvant chemotherapy in nasopharyngeal malignancies” 
 
Study Title:_____________________ 
Study Number: __________________ 
Subject’s Initials: __________________  
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
 
(i) I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions. 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. 
(iii) I understand that the Ethics Committee and the regulatory authorities will not need 
my permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the trial. I 
agree to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
(v) I agree to take part in the above study. 
(vi)I agree to give my blood sample for EBV DNA titres which would be done at a later date. 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature (or thumb impression) of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name & Address of the Witness: ______________________________ 
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Annexure 3: Clinical Research Form 
 
PROFORMA SHEET  
DWI-MRI in Nasopharyngeal cancer study  
Name:  
Age:  
Sex:  
Diagnosis:  
Radiotherapy dose:  
Chemotherapy agent:  
No. of Cycles:  
 
Pretreatment Signal Intensity:  
Pretreatment Size:  
Pretreatment ADC1:  
Pretreatment ADC2:  
Pretreatment ADC3:  
Pretreatment ADC4:  
 
1 st Week Signal Intensity:  
1 st Week Size:  
1 st Week ADC1:  
1 st Week ADC2:  
1 st Week ADC3:  
1 st Week ADC4:  
 
At completion Signal Intensity:  
At completion Size:  
At completion ADC1:  
At completion ADC2:  
At completion ADC3:  
At completion ADC4: 
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Annexure 4: Raw data 
 
 
 
